Galapagos' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study
Didn't make notes yet but a Couple Comments from first listen: 1-Abbvie has 60 days from Darwin 2 ("any day") results to decide on licensing. Would "gladly" wave criteria requiring them to listen if they are not interested. 2-1 Death happened because of Pneumonia not clear if drug related as happened in hospital outside of investigator. 3 Weeks prior blood work was normal (nothing to show concern). 3-Not concerned with high dose in male patients. Monitored male hormone and no safety signal also in Darwin 3 much more males on high dose also did preclinical studies that think give freedom to operate.